Experimental diabetes drug AP026 tested in early trial – but study halted
NCT ID NCT06143423
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called AP026, a fusion protein that targets two pathways (GLP-1 and FGF21) to potentially treat type 2 diabetes. The study planned to enroll 74 healthy adults but was terminated early after only 14 participants. The main goal was to check safety and how well the drug is tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AP026 (a GLP-1-FGF21 fusion protein)
- What this could lead to
- If successful, this could lead to a new treatment option for type 2 diabetes that helps control blood sugar and weight.
- What could go wrong
- This was a very early (Phase 1) trial that was terminated early, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The first hospital of Jilin University
Changchun, Jilin, 130061, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a heart drug tame blood sugar and weight in diabetes?
- Can a puff of insulin replace a needle for diabetes?
- Could a quick insulin shot stop Steroid-Induced blood sugar spikes?
- Can a puff of insulin replace a daily shot for diabetes?
- Could a Dairy-Rich diet tame type 2 diabetes?
- Can a traditional herbal remedy tame type 2 diabetes?